In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cidara Therapeutics Inc.

www.cidara.com

Latest From Cidara Therapeutics Inc.

Deal Watch: BMS To Tap Early-Stage Breakthroughs In Partnership With BioMotiv

Bristol-Myers Squibb will partner with the biotech accelerator to fund and launch biotechs, with the pharma getting an option to buy. Novartis signs another agreement with IFM months after buying its IFM Tre affiliate.

Deals Business Strategies

Cidara's Once-Weekly Antifungal Gets Phase III Boost From Mundipharma

Mundipharma is to provide financial support and development expertise for Cidara’s Phase III clinical studies of its once-weekly echinocandin antifungal for serious infections, in return for ex-US and ex-Japanese marketing rights.

 

Infectious Diseases Deals

Latest Phase II Data Bolster Cidara’s Antifungal

Cidara Therapeutics said new top-line results from the Phase II trial evaluating its lead asset as a first-line antifungal treatment in patients with candidemia and invasive candidiasis supported its ongoing Phase III ReSTORE program.
Clinical Trials Commercial

Antibiotic Incentives: Advocates Sounding The Alarm For DISARM

Antibiotic developers have a blunt message for Congress: the time for action is now or never. They see a targeted reimbursement change (The DISARM Act) as vital to send a signal to investors that the sector can be saved – and don’t want to delay to debate other ideas like “subscription” models.

Infectious Diseases Legislation
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Infectious & Viral Diseases
  • Alias(es)
  • K2 Therapeutics
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Cidara Therapeutics Inc.
  • Senior Management
  • Jeffrey Stein, PhD, Pres. & CEO
    James Levine, CFO
    Taylor Sandison, MD, CMO
    Neil Abdollahian, CBO
    Les Tari, PhD, SVP, Rsch.
  • Contact Info
  • Cidara Therapeutics Inc.
    Phone: (858) 752-6170
    6310 Nancy Ridge Dr., Ste. 101
    San Diego, CA 92121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register